BOTHELL, Wash., April 18 /PRNewswire-FirstCall/ -- Helix BioMedix, Inc.
(OTC: HXBM.OB), a developer of bioactive peptides, today announced that
members of its scientific staff will be presenting its novel antimicrobial
hexapeptides at three industry conferences in May 2006. Dr. Timothy Falla,
the company's Chief Scientific Officer, will present at TIDES(R) on May 1,
2006; Dr. Scott M. Harris, Director of Chemistry, will present at the Wound
Healing Society 16th Annual Meeting and Exhibition on May 17, 2006; and Dr.
Lijuan Zhang, Principal Scientist, will present at the 106th American
Society for Microbiology Annual General Meeting on May 25, 2006.
"We are excited to have the opportunity to discuss recent advances
related to our new class of hexapeptides at such important industry
events," commented Dr. Falla. "In preclinical studies, these hexapeptides
have activities previously thought to be restricted to peptides in excess
of 15 residues in length. Not only are they more stable and active in
biological environments, but they have many characteristics of therapeutic
drugs and are capable of combating an increasing number of drug-resistant
bacterial and fungal infections. They also appear to have low toxicity and
are expected to be cost-effective to manufacture, key qualities required
for commercial success. Dermatological applications we are working on
include acne, dermatitis and rosacea."
Specific conference information is as follows:
TIDES(R) -- Oligonucleotide and Peptide Technology and Product
Development Conference 2006 titled "Proven Strategies for Successful Drug
and Diagnostic Development" is being held May 1-4, 2006 at the La Costa
Resort and Spa, Carlsbad, CA. Dr. Timothy Falla's presentation titled
"Antimicrobial Hexapeptides: Structure, Activity and Cost" is scheduled for
May 1, 2006 at 4:15PM PT (Track 2). TIDES(R) 2006 provides superior
information and networking to scientists and executives involved in
manufacturing therapeutics; raw materials, services and equipment for
therapeutics; and diagnostics.
The Wound Healing Society 16th Annual Meeting & Exhibition is being
held May 14-17, 2006 at the Double Tree Paradise Valley, Scottsdale, AZ.
Dr. Scott M. Harris is presenting an abstract titled "Novel Hexapeptide
Antimicrobials for the Prevention of Wound Infection" on May 17, 2006 at
3:00 pm local time during Concurrent Session #8 Wound Infection /
Inflammation Response. Authors of the abstract include Dr. Scott M Harris,
Dr. Lijuan Zhang, Dr. Jody Parente and Dr. Timothy J. Falla, all of Helix
BioMedix, Inc. The Wound Healing Society, founded in 1990, is recognized
among professionals and government agencies as the leading scientific
organization focused on the area of wound healing.
The 106th American Society for Microbiology Annual General Meeting is
being held May 21-25, 2006 at the Orange County Convention Center in
Orlando, FL. Dr. Lijuan Zhang is presenting a poster of an Abstract titled
"Novel Class of Hexapeptide Anti-Infective: A Structure Activity Profile"
on May 25, 2006. Authors include Dr. Lijuan Zhang, Dr. Jody Parente, Dr.
Scott M. Harris and Dr. Timothy Falla, all of Helix BioMedix, Inc. The
American Society for Microbiology is the largest annual gathering of
microbiologists in the world and showcases exciting advances and
controversies in clinical microbiology and epidemiology, pathogenesis and
host defense, general and applied microbiology, microbial physiology,
genetics and molecular biology, environmental microbiology, parasitology
and virology.
About Helix BioMedix
Helix BioMedix, Inc. is a biopharmaceutical company that has a
portfolio of issued patents that covers six distinct classes of peptides,
including over 100,000 unique peptide sequences. The company's mission is
to become the industry leader in developing and commercializing small
proteins known as bioactive peptides. The antimicrobial and wound healing
properties of these peptides qualify them for inclusion in a wide range of
both pharmaceutical and consumer products. The company is currently focused
on the development of selected peptides as topical anti-infectives and in
wound healing applications. Non-pharmaceutical applications being pursued
by Helix BioMedix include adjuvants for cosmetics/cosmeceuticals, personal
care, plant health, animal health and wide-spectrum biocides. More
information about the company and its proprietary peptides can be found on
the company's website at http://www.helixbiomedix.com.
Important Notice
This press release contains forward-looking statements (statements
which are not historical facts) within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking statements
include statements regarding activities, events or developments that the
company expects, believes or anticipates may occur in the future, including
statements related to our potential growth, product development and
commercialization and revenue. A number of factors could cause actual
results to differ from those indicated in the forward-looking statements,
including the company's ability to successfully raise additional capital,
enter into revenue generating license agreements, continue its research and
development efforts, including pre-clinical and clinical studies, and
general economic conditions. Additional assumptions, risks and
uncertainties are described in detail in our reports and other filings with
the Securities and Exchange Commission. Such filings are available on our
website or at http://www.sec.gov. Readers are cautioned that such forward-looking
statements are not guarantees of future performance and that actual results
or developments may differ materially from those set forth in the
forward-looking statements. The company undertakes no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances.
Contact:
Helix BioMedix, Inc.
David H. Kirske, 425-402-8400
dkirske@helixbiomedix.com
or:
Investor Relations:
Cameron Associates
Alison Ziegler, 212-554-5469
alison@cameronassoc.com
SOURCE Helix BioMedix, Inc.
 back to top
Related links:
http://www.helixbiomedix.com/
CONTACT:
David H. Kirske of Helix BioMedix, Inc.,
+1-425-402-8400, or dkirske@helixbiomedix.com; or investors,
Alison Ziegler of Cameron Associates, +1-212-554-5469, or
alison@cameronassoc.com, for Helix BioMedix, Inc.
|
